Project Description

Member, Clinical Research Division, FHCRC
Giuliani/Press Endowed Chair in Cancer Research
Professor of Medicine and Bioengineering (Adjunct), University of Washington
ude.1516673700wu@ss1516673700erp1516673700

Not currently accepting graduate students.

Adoptive T cell immunotherapy
Pretargeted radioimmunotherapy
Antibody/drug conjugates
Dr. Press investigates novel treatments for hematologic malignancies including lymphoma, leukemia, and myeloma. He conducts basic laboratory investigations using leukemia and lymphoma cell lines and mouse xenograft models as well as human clinical trials. Agents currently under investigation include monoclonal antibodies, radioimmunoconjugates, immunotoxins, chemotherapeutic agents, and genetically modified cytotoxic T lymphocytes. In the clinical arena, he has a successful program of high dose radioimmunotherapy with stem cell transplantation for B cell lymphomas and has trials planned investigating pretargeted radioimmunotherapy and gene therapy using adoptively transferred cytotoxic T lymphocytes bearing chimeric anti-CD20 receptors.
MD, University of Washington, Seattle, 1979
PhD in Biological Structure, University of Washington, Seattle, 1977
B.S. in Biology, Stanford University, 1973